US EditionPublished • loading... • Updated
cbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement
cbdMD raised $2.25 million through Series C Convertible Preferred Stock with a 10% dividend to fund working capital and strategic growth, company said.
- On December 19, 2025, cbdMD finalized a private placement issuing 1,000,000 Series C Convertible Preferred Stock for $2.1 million in gross proceeds, entering into securities purchase agreements with institutional investors.
- The company, parent of Herbal Oasis, ATRx and Paw CBD, distributes U.S.-produced cannabinoid products online and through thousands of retail outlets across the United States.
- The Series C terms show Series C Convertible Preferred Stock carries a 10% annual dividend and converts at the holder's option at an initial $2.25 per share, with anti-dilution protection.
- Net proceeds of approximately $2.1 million will fund working capital, general corporate purposes and ongoing strategic initiatives, Ronan Kennedy, Chief Executive Officer and Chief Financial Officer, said.
- The company warned that the press release contains forward-looking statements subject to risks under the U.S. Private Securities Litigation Reform Act of 1995 and urges investors to review cautionary statements and the Form 10-K for fiscal year ended September 30, 2024 filed December 17, 2024.
Insights by Ground AI
34 Articles
34 Articles
Bennington Banner+32 Reposted by 32 other sources
cbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement
CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading wellness company and the parent of Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw CBD, today announces that it has entered into securities purchase…
Coverage Details
Total News Sources34
Leaning Left3Leaning Right3Center10Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 19%
C 62%
R 19%
Factuality
To view factuality data please Upgrade to Premium
